Inhibition of morphine tolerance and physical dependence development and brain serotonin synthesis by cycloheximide.
D000498:Allyl Compounds / Q000494:pharmacology; D000818:Animals; D001835:Body Weight; D001921:Brain / Q000378:metabolism; D002247:Carbon Isotopes; D002855:Chromatography, Thin Layer; D003513:Cycloheximide / Q000008:administration & dosage / Q000494:pharmacology*; D004361:Drug Tolerance / Q000187:drug effects; D004988:Ethers, Cyclic / Q000494:pharmacology; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007668:Kidney / Q000032:analysis; D008099:Liver / Q000032:analysis; D008297:Male; D051379:Mice; D009019:Morphinans / Q000494:pharmacology; D009020:Morphine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D009021:Morphine Dependence / Q000378:metabolism* / Q000401:mortality / Q000517:prevention & control; D010293:Pargyline / Q000494:pharmacology; D012701:Serotonin / Q000096:biosynthesis* / Q000378:metabolism; D013997:Time Factors
D000498:Allyl Compounds; D002247:Carbon Isotopes; D004988:Ethers, Cyclic; D009019:Morphinans; D012701:Serotonin; D009020:Morphine; D003513:Cycloheximide; D010293:Pargyline